EBS
Price
$2.54
Change
-$0.06 (-2.31%)
Updated
Mar 28, 6:59 PM EST
28 days until earnings call
GNPX
Price
$3.00
Change
+$0.27 (+9.89%)
Updated
Mar 28, 2:08 PM EST
One day until earnings call
Ad is loading...

Compare predictions EBS vs GNPX

Header iconEBS vs GNPX Comparison
Open Charts EBS vs GNPXBanner chart's image
Emergent Biosolutions
Price$2.54
Change-$0.06 (-2.31%)
Volume$370.31K
CapitalizationN/A
Genprex
Price$3.00
Change+$0.27 (+9.89%)
Volume$100
CapitalizationN/A
View a ticker or compare two or three
EBS vs GNPX Comparison Chart

Loading...

EBSDaily Signal changed days agoGain/Loss if shorted
 
Show more...
GNPXDaily Signal changed days agoGain/Loss if shorted
 
Show more...
VS
EBS vs. GNPX commentary
Mar 28, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is EBS is a StrongBuy and GNPX is a Hold.

COMPARISON
Comparison
Mar 28, 2024
Stock price -- (EBS: $2.54 vs. GNPX: $2.71)
Brand notoriety: EBS and GNPX are both not notable
EBS represents the Pharmaceuticals: Other, while GNPX is part of the Biotechnology industry
Current volume relative to the 65-day Moving Average: EBS: 10% vs. GNPX: 34%
Market capitalization -- EBS: $135.21M vs. GNPX: $5.18M
EBS [@Pharmaceuticals: Other] is valued at $135.21M. GNPX’s [@Biotechnology] market capitalization is $5.18M. The market cap for tickers in the [@Pharmaceuticals: Other] industry ranges from $77.16B to $0. The market cap for tickers in the [@Biotechnology] industry ranges from $576.05B to $0. The average market capitalization across the [@Pharmaceuticals: Other] industry is $2.97B. The average market capitalization across the [@Biotechnology] industry is $2.64B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

EBS’s FA Score shows that 1 FA rating(s) are green whileGNPX’s FA Score has 1 green FA rating(s).

  • EBS’s FA Score: 1 green, 4 red.
  • GNPX’s FA Score: 1 green, 4 red.
According to our system of comparison, EBS is a better buy in the long-term than GNPX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

EBS’s TA Score shows that 7 TA indicator(s) are bullish while GNPX’s TA Score has 4 bullish TA indicator(s).

  • EBS’s TA Score: 7 bullish, 3 bearish.
  • GNPX’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, EBS is a better buy in the short-term than GNPX.

Price Growth

EBS (@Pharmaceuticals: Other) experienced а +2.63% price change this week, while GNPX (@Biotechnology) price change was -9.06% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +8.73%. For the same industry, the average monthly price growth was +5.34%, and the average quarterly price growth was +13.58%.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.98%. For the same industry, the average monthly price growth was +5.11%, and the average quarterly price growth was +88.96%.

Reported Earning Dates

EBS is expected to report earnings on Apr 25, 2024.

GNPX is expected to report earnings on May 29, 2024.

Industries' Descriptions

@Pharmaceuticals: Other (+8.73% weekly)

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

@Biotechnology (+4.98% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
A.I.dvisor published
a Summary for EBS with price predictions.
OPEN
A.I.dvisor published
a Summary for GNPX with price predictions.
OPEN
FUNDAMENTALS
Fundamentals
EBS($135M) has a higher market cap than GNPX($5.18M). EBS YTD gains are higher at: 5.625 vs. GNPX (-70.543). GNPX has higher annual earnings (EBITDA): -31.65M vs. EBS (-518.2M). EBS has more cash in the bank: 112M vs. GNPX (11.7M). GNPX has less debt than EBS: GNPX (279K) vs EBS (860M). EBS has higher revenues than GNPX: EBS (1.02B) vs GNPX (0).
EBSGNPXEBS / GNPX
Capitalization135M5.18M2,608%
EBITDA-518.2M-31.65M1,637%
Gain YTD5.625-70.543-8%
P/E Ratio17.73N/A-
Revenue1.02B0-
Total Cash112M11.7M957%
Total Debt860M279K308,244%
FUNDAMENTALS RATINGS
EBS vs GNPX: Fundamental Ratings
EBS
GNPX
OUTLOOK RATING
1..100
875
VALUATION
overvalued / fair valued / undervalued
1..100
66
Overvalued
11
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9899
PRICE GROWTH RATING
1..100
6497
P/E GROWTH RATING
1..100
18100
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

GNPX's Valuation (11) in the Pharmaceuticals Major industry is somewhat better than the same rating for EBS (66) in the Biotechnology industry. This means that GNPX’s stock grew somewhat faster than EBS’s over the last 12 months.

GNPX's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as EBS (100) in the Biotechnology industry. This means that GNPX’s stock grew similarly to EBS’s over the last 12 months.

EBS's SMR Rating (98) in the Biotechnology industry is in the same range as GNPX (99) in the Pharmaceuticals Major industry. This means that EBS’s stock grew similarly to GNPX’s over the last 12 months.

EBS's Price Growth Rating (64) in the Biotechnology industry is somewhat better than the same rating for GNPX (97) in the Pharmaceuticals Major industry. This means that EBS’s stock grew somewhat faster than GNPX’s over the last 12 months.

EBS's P/E Growth Rating (18) in the Biotechnology industry is significantly better than the same rating for GNPX (100) in the Pharmaceuticals Major industry. This means that EBS’s stock grew significantly faster than GNPX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
EBSGNPX
RSI
ODDS (%)
Bearish Trend 2 days ago
88%
Bullish Trend 2 days ago
85%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
73%
Bullish Trend 2 days ago
77%
Momentum
ODDS (%)
Bullish Trend 2 days ago
67%
Bearish Trend 2 days ago
89%
MACD
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
86%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
74%
Bearish Trend 2 days ago
90%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
84%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 11 days ago
74%
Bullish Trend 7 days ago
78%
Declines
ODDS (%)
Bearish Trend 7 days ago
86%
Bearish Trend 2 days ago
89%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 2 days ago
82%
Aroon
ODDS (%)
Bullish Trend 2 days ago
74%
Bearish Trend 2 days ago
90%
View a ticker or compare two or three
Ad is loading...
EBSDaily Signal changed days agoGain/Loss if shorted
 
Show more...
GNPXDaily Signal changed days agoGain/Loss if shorted
 
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
PMYYX39.69N/A
N/A
Putnam Core Equity Fund Y
USTCX24.38N/A
N/A
Victory Science & Technology Class A
DFSGX24.10N/A
N/A
DF Dent Small Cap Growth Institutional
LTAGX14.04N/A
N/A
Lord Abbett International Growth R5
AILLX22.98N/A
N/A
Aristotle Core Equity I-2

GNPX and

Correlation & Price change

A.I.dvisor indicates that over the last year, GNPX has been loosely correlated with BCTX. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if GNPX jumps, then BCTX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GNPX
1D Price
Change %
GNPX100%
-1.09%
BCTX - GNPX
36%
Loosely correlated
+5.51%
AXON - GNPX
30%
Poorly correlated
-1.13%
ARRY - GNPX
30%
Poorly correlated
+6.94%
BDTX - GNPX
29%
Poorly correlated
-3.73%
RVNC - GNPX
28%
Poorly correlated
+4.89%
More